Additionally, considering that minimal residual myeloma cells express stem-like genes such as CD24, Sun et al. 56 constructed a bispecific BCMA-CD24-CAR-T cell therapy and revealed that this dual-targeted CAR-T cells exhibited increased cytolytic activity and prolonged survival in xenograft models compared to monospecific anti-BCMA CAR-T treatment. Here, TNFRSF17 is linked to plasma cell myeloma.